Rare Kidney Cancer


United States

Organ System:


Funding Organization:

  • National Institutes of Health, USA

Research Organizations:

  • University of Michigan, USA
  • Johns Hopkins University, USA
  • Icahn School of Medicine at Mount Sinai, USA
  • Washington University in St. Louis, USA
  • Broad Institute of MIT and Harvard, USA
  • National Cancer Institute, USA

Principal Investigators:

  • Alexey I. Nesvizhskii
  • Hui Zhang
  • Saravana M. Dhanasekaran


External Links:

Non-clear cell renal cell carcinomas (non-ccRCCs) encompass diverse malignant and benign tumors. Refinement of differential diagnosis biomarkers, markers for early prognosis of aggressive disease, and therapeutic targets to complement immunotherapy are current clinical needs. Multi-omics analyses of 48 non-ccRCCs compared with 103 ccRCCs reveal proteogenomic, phosphorylation, glycosylation, and metabolic aberrations in RCC subtypes. RCCs with high genome instability display overexpression of IGF2BP3 and PYCR1. Integration of single-cell and bulk transcriptome data predicts diverse cell-of-origin and clarifies RCC subtype-specific proteogenomic signatures. Expression of biomarkers MAPRE3, ADGRF5, and GPNMB differentiates renal oncocytoma from chromophobe RCC, and PIGR and SOSTDC1 distinguish papillary RCC from MTSCC. This study expands our knowledge of proteogenomic signatures, biomarkers, and potential therapeutic targets in non-ccRCC.